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Abstract
Measles and rubella persist in the World Health Organization European Region despite long-standing and widespread use of vaccines against
them. Our aim was to review the epidemiology of measles and rubella in relation to the goal of eliminating these diseases from the Region by
2015. We report on the number of measles and rubella cases by country in 2012 and present an analysis of preliminary measles and rubella
surveillance data for 2013. We analysed data of these diseases for 2013 by age group, diagnosis conﬁrmation (clinical, laboratory-conﬁrmed
and epidemiologically linked), and vaccination, hospitalization and importation status. We also report on measles-related deaths. For 2012,
there were 27 134 measles cases and 29 601 rubella cases reported in the Region. For 2013, these ﬁgures were 31 520 and 39 367
respectively. Most measles cases in 2013 (96%; n = 30 178) were reported by nine countries: Georgia (7830), Germany (1773), Italy (2216),
the Netherlands (2499), Romania (1074), the Russian Federation (2174), Turkey (7404), Ukraine (3308) and the United Kingdom (1900). In
2013, most measles cases were among unvaccinated persons and over one in three patients were aged 20 years and older. For 2013, almost
all rubella cases were reported by Poland (n = 38 585; 98%). High population immunity and high-quality surveillance are the cornerstones
to eliminate measles and rubella. Without sustained political commitment and accelerated action by Member States and partners, the
elimination of measles and rubella in the WHO European Region may not be achieved.
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Background
Despite substantial progress made towards controlling mea-
sles and rubella in the World Health Organization (WHO)
European Region, the regional target of measles and rubella
elimination by 2015 is in jeopardy. The Region comprises 53
Member States [1] that together have a population of just
over 900 million. All countries use measles- and rubella--
containing vaccines, usually in combination with a mumps
vaccine.
To assess the status of measles and rubella in the Region in
relation to the elimination target, we report on the number of
measles and rubella cases in 2012 and review the epidemi-
ological data on these diseases for 2013. We also discuss the
current challenges faced and the actions needed to reach this
goal.
Methods
We report on the number of measles and rubella cases by
country in 2012 and present an analysis of preliminary measles
and rubella surveillance data for 2013, as of 31 January 2014.We
analysed data submitted by national surveillance institutions to
the Centralized Information System for Infectious Diseases
(CISID) [2] of theWHO Regional Ofﬁce for Europe. Data from
the 28 Member States of the European Union, Iceland and
Norway were entered into CISID after collection and process-
ing by The European Surveillance System (TESSy), of the
European Centre for Disease Prevention and Control [3].
We also report on measles and rubella virus sequence data
as entered in the Measles Nucleotide Surveillance database
(MeaNS) [4] and Rubella Nucleotide Surveillance database
(RubeNS) [5], respectively, by national or reference laborato-
ries of the WHO European Region as of 31 January 2014.
We analysed cases of measles and rubella with disease onset
dates in 2013 by age group, diagnosis conﬁrmation and
vaccination, hospitalization and importation status. Cases were
separated by age: <1 year, 1–4 years, 5–9 years, 10–14 years,
15–19 years and ≥ 20 years. In addition, we report on
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measles-related deaths that occurred in 2012 and 2013 up to
the time of submitting this article.
Incidence of disease was calculated with the number of
cases of reported measles and rubella as the numerator and
the country population obtained from the Population Division
of the United Nations Organization [6] as the denominator.
We expressed incidence of disease as cases per million
inhabitants per year. We included all reported cases (including
indigenous cases, imported cases, import-related cases and
cases with unknown importation status) when calculating
crude incidences. Poisson regression was used to estimate 95%
conﬁdence intervals (CI).
Results
Measles
For 2012, 27 134 measles cases were reported in 41 countries
of the WHO European Region. For 2013, there were 31 520
measles cases were reported in 38 countries among 50 (94%)
countries that submitted measles data (including zero report-
ing). Three countries, Bosnia and Herzegovina, Monaco and
San Marino, did not submit reports. Most cases in 2013 (96%;
n = 30 178) were reported by nine countries: Georgia (7830;
25%), Germany (1773; 6%), Italy (2216; 7%), the Netherlands
(2499; 8%), Romania (1074; 3%), the Russian Federation (2174;
7%), Turkey (7404; 23%), Ukraine (3308; 10%) and the United
Kingdom (1900; 6%). The highest incidence per million
inhabitants for 2013 was reported in Georgia (1803.8; 95%
CI 1764.3–1844.2) followed by the Netherlands (149.1; 95% CI
143.4–155.1). Table 1 shows the number and crude incidence
of reported measles for 2012 and 2013 in the Region.
For 2013, measles virus sequencing was performed in 1110
cases from 25 countries. The genotypes identiﬁed in the Region
included D8 (n = 921), D4 (102), B3 (72), D9 (6) and H1 (3).
The age group was known in 99.9% (n = 31 502) of cases.
Overall, 13% (n = 4017) were <1 year old, 19% (5972) were 1–
4 years old, 14% (4449) were 5–9 years old, 10% (3186) were
10–14 years old, 10% (3238) were 15–19 years old and 34% (10
640) were ≥20 years old. The age distribution varied between
countries. Among the nine countries that reported most
measles cases in the Region (Fig. 1), the largest proportion of
cases in adults aged ≥20 years was reported from Italy (59%;
n = 1318) followed by Georgia (51%; 4015) and the Russian
Federation (50%; 1096). By contrast, the largest proportion of
cases in children aged 1–4 years was reported in Romania (39%;
415), followed by Turkey (26%; 1886) and Ukraine (24%; 789).
Vaccination status was known in 22 192 cases (70%). Of
the 16 607 (75%) cases classiﬁed as unvaccinated, age was
known for 16 600 of them: 3764 cases (23%) were <1 year
old, 3282 cases (20%) were 1–4 years old, 2290 cases (14%)
were 5–9 years old, 3639 cases (22%) were 10–19 years old
and 3625 cases (22%) were aged ≥20 years. The remaining
5585 cases (25%) were vaccinated with at least one
measles-containing vaccine dose.
One measles-related death was reported in the Region for
2012. The death was reported from Spain and occurred in a
36-year-old man. Seven measles-related deaths were reported
for 2013, corresponding to a death rate per 1000 measles cases
of 0.22 (95% CI 0.11–0.46). The deaths were reported from
Georgia (two deaths), the Netherlands (one death), Romania
(one death), Turkey, (two deaths) and the United Kingdom
(one death). The ages of fatal cases were <1 year (two cases),
9 years, 17 years, 19 years, 25 years and 31 years.
Data on hospitalization status were available for 62%
(n = 19 500) of all reported measles cases for 2013. There
were 8271 reported hospitalized cases in connection with
measles, amounting to 42% of all cases with known hospital-
ization status.
Importation status was known in 59% (n = 18 570) of cases,
of which 308 were reported as imported cases (1.7%). The
remaining cases were believed to have been infected within
their own countries.
Rubella
For 2012, 29 601 rubella cases were reported in 28 countries
of the WHO European Region. For 2013, 39 367 rubella cases
were reported in 21 countries of the WHO European Region
among 43 (81%) countries submitting rubella data (including
zero reporting). The cases were reported almost exclusively
by Poland (n = 38 585; 98%), which also had the highest
incidence per million population (1009.6; 95% CI 999.6–
1019.8). Table 2 shows the number and crude incidence of
reported rubella for 2012 and 2013 in the Region.
For 2013, one rubella virus sequence was entered in the
RubeNS database by the reference laboratory of the United
Kingdom. The genotype identiﬁed was 2B.
The age group was known in 5302 cases (13%), of which
131 cases (2%) were <1 year old, 365 cases (7%) were
1–4 years old, 389 cases (7%) were 5–9 years old, 167 cases
(3%) were 10–14 years old, 2709 cases (51%) were 15–
19 years old and 1541 cases (29%) were aged ≥20 years.
Vaccination status was known in 25 459 cases (65%). Of the
21 130 (83%) unvaccinated cases, 364 cases had data on age: 61
cases (17%) were <1 year old, 47 cases (13%) were 1–4 years
old, 17 cases (5%) were 5–9 years old, 69 cases (19%) were 10–
19 years old and 170 cases (47%) were aged ≥20 years. The
remaining 4329 cases (17%) were reportedly vaccinated with at
least one rubella-containing vaccine dose. These were reported
mostly by Poland (95%; n = 4125).
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication., CMI, 20 (Suppl. 5), 12–18
CMI Muscat et al. Measles and rubella in the WHO European Region 13
Importation status was known in 1% (n = 478) of rubella
cases. Of these, 15 cases (3.1%) were reported as imported.
The remaining cases were believed to have been infected
within their own countries.
Discussion
Widespread outbreaks and endemic transmission of measles
and rubella persisted in the Region in 2013, threatening the
regional target of measles and rubella elimination. Despite
high vaccination coverage at regional level and in most
Member States [7], sub-optimal coverage rates in some areas
and immunity gaps in the population remain the primary cause
of continued measles or rubella transmission in 2013. With
over a third of patients with measles in the Region aged
≥20 years, adults have emerged as a susceptible group for
measles.
Most measles and rubella outbreaks occurred in the general
population but as in previous years outbreaks have also
TABLE 1. Incidence per 1 000 000 population of measles in the WHO European Region, 2012 and 2013
Number of measles
cases
Crude incidence per
million inhabitants Number of measles cases 2013
2012 2013 2012 2013
Laboratory
conﬁrmed
Epidemiologically
linked
Clinical
cases
Albania 0 0 0 0 0 0 0
Andorra 0 0 0 0 0 0 0
Armenia 0 11 0 3.7 7 4 0
Austria 35 75 4.1 8.8 51 13 11
Azerbaijan 2 164 0.2 17.4 161 3 0
Belarus 12 16 1.3 1.7 16 0 0
Belgium 101 38 9.1 3.4 22 0 16
Bosnia and Herzegovina – – – – – – –
Bulgaria 1 16 0.1 2.2 13 1 2
Croatia 3 0 0.7 0 0 0 0
Cyprus 1 0 0.9 0 0 0 0
Czech Republic 21 14 2.0 1.3 13 1 0
Denmark 2 17 0.4 3.0 17 0 0
Estonia 4 2 3.1 1.6 2 0 0
Finland 4 2 0.7 0.4 2 0 0
France 859 272 13.4 4.2 121 12 139
Georgia 30 7830 6.9 1803.8 787 257 6786
Germany 167 1773 2.0 21.4 1036 481 256
Greece 3 2 0.3 0.2 2 0 0
Hungary 1 1 0.1 0.1 1 0 0
Iceland 0 0 0 0 0 0 0
Ireland 104 56 22.7 12.1 33 10 13
Israel 149 57 19.5 7.4 16 6 35
Italy 607 2216 10.0 36.3 1174 593 449
Kazakhstan 109 73 6.7 4.4 62 9 2
Kyrgyzstan 0 1 0 0.2 1 0 0
Latvia 3 0 1.5 0 0 0 0
Lithuania 2 35 0.7 11.6 35 0 0
Luxembourg 2 0 3.8 0 0 0 0
Malta 0 2 0 4.7 2 0 0
Monaco 1 – 26.6 – – – –
Montenegro 0 0 0 0 0 0 0
Netherlands 10 2499 0.6 149.1 811 1688 0
Norway 4 8 0.8 1.6 8 0 0
Poland 73 85 1.9 2.2 55 5 25
Portugal 7 0 0.7 0 0 0 0
Republic of Moldova 11 27 3.1 7.7 20 7 0
Romania 6164 1074 283.3 49.5 817 232 25
Russian Federation 1979 2174 13.8 15.2 2038 129 7
San Marino – – – – – – –
Serbia 0 1 0 0.1 1 0 0
Slovakia 1 0 0.2 0 0 0 0
Slovenia 2 1 1.0 0.5 1 0 0
Spain 1210 127 25.9 2.7 105 14 8
Sweden 31 51 3.3 5.3 50 1 0
Switzerland 61 183 7.6 22.7 111 21 51
Tajikistan 7 1 0.9 0.1 0 0 1
The former Yugoslav
Republic of Macedonia
6 4 2.8 1.9 3 0 1
Turkey 698 7404 9.4 98.8 7384 19 1
Turkmenistan 0 0 0 0 0 0 0
Ukraine 12 744 3308 279.9 73.1 1195 0 2113
United Kingdom 1903 1900 30.3 30.1 1900 0 0
Uzbekistan 0 0 0 0 0 0 0
Total 27 134 31 520 30.1* 34.9* 18 073 3506 9941
There may be differences in numbers documented in reports based on data derived from the WHO/UNICEF Joint Reporting Form – the data we present for 2012 include updated
numbers reported by some countries and for 2013, the data may be updated following the publication of this article. Discrepancies might also arise with nationally reported data if
these include cases by year of notiﬁcation rather than year of disease onset.
*Populations of countries without reports were excluded from the denominator.
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affected particular groups [8,9]. In 2012, an outbreak of rubella
in Sweden, resulting in 50 cases occurred mostly in an
anthroposophic community [10]. In 2013, an outbreak of
measles in the Netherlands resulting in 1226 cases by 28
August occurred mostly among unvaccinated orthodox Prot-
estants. At the same time the country also experienced an
outbreak of rubella with 54 cases, all linked to a primary school
of orthodox Protestant denomination [11,12].
It is reasonable to assume that the age distribution of
measles cases in different countries reﬂects the susceptible
populations by age. Although we did not include national
data on vaccination strategies and coverage, the accumula-
tion of susceptible groups is most likely a result of
ﬂuctuating vaccination coverage levels over the years.
Moreover, adults not targeted when measles vaccination
programmes were ﬁrst implemented in their countries >20
years ago are still susceptible if they never acquired the
disease nor received the vaccine. An increased level of
clinical suspicion of measles and rubella in cases with rash,
particularly in patients who are ≥20 years old and in
travellers returning from countries where these infections
are endemic, is therefore important.
Suspected cases of measles and rubella should be notiﬁed
promptly to public health authorities to allow timely
case-based investigation and tracing of contacts for vaccina-
tion, if necessary. In addition, laboratory investigations,
including molecular characterization of measles and rubella
viruses, are critical to identify imported viruses, deﬁne
import-related outbreaks and understand transmission
patterns, thereby contributing to the assessment of inter-
ruption of endemic transmission. The extent of laboratory
conﬁrmation of suspected measles and rubella cases varied
between countries in 2013 depending on the absence or
presence of outbreaks and on the quality of surveillance.
Genotype information on the circulating the measles virus
was available in MeaNS from almost all countries which
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N.B. Discarded cases are not included. In 11 cases from Turkey and one case form Germany the age was not known. 
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FIG. 1. Age distribution of measles cases in the nine countries that reported most cases in the WHO European Region, 2013 (n = 30 166).
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reported outbreaks in the European Region in 2013. These
data provide a good indication of the dynamics of measles virus
molecular epidemiology in the Region. Nevertheless, since the
proportion of cases with laboratory conﬁrmation and the
laboratory viral sequencing strategies vary widely among
countries, more efforts are needed to enhance laboratory
surveillance not only for measles but also for rubella.
In 2012, the WHO Regional Ofﬁce for Europe has
developed an online Measles and Rubella Laboratory Data
Management System (MR LDMS) for the Regional Measles
Rubella Laboratory Network (MR Labnet) to enable timely
linkage of case-based epidemiological and laboratory data [13].
The system will replace monthly aggregate reporting of
laboratory data to CISID during 2014 and this will become
an essential tool to verify the elimination of measles and
rubella.
The rubella cases in 2013 were reported almost exclusively
from Poland. The large extent of the outbreak could only allow
TABLE 2. Incidence per 1 000 000 population of rubella in the WHO European Region, 2012 and 2013
Number of rubella
cases
Crude incidence per
million inhabitants Number of rubella cases 2013
2012 2013 2012 2013
Laboratory
conﬁrmed
Epidemiologically
linked
Clinical
cases
Albania 1 0 0.3 0 0 0 0
Andorra 0 0 0 0 0 0 0
Armenia 1 4 0.3 1.3 4 0 0
Austria 23 11 2.7 1.3 8 1 2
Azerbaijan 0 0 0 0 0 0 0
Belarus 9 1 1.0 0.1 1 0 0
Belgium – – – – – – –
Bosnia and Herzegovina – – – – – – –
Bulgaria 19 8 2.6 1.1 0 1 7
Croatia 0 1 0 0.2 1 0 0
Cyprus 0 0 0 0 0 0 0
Czech Republic 5 0 0.5 0 0 0 0
Denmark – – – – – – –
Estonia 0 2 0 1.6 2 0 0
Finland 0 2 0 0.4 2 0 0
France – – – – – – –
Georgia 67 220 15.4 50.7 5 1 214
Germany – – – – – – –
Greece 0 0 0 0 0 0 0
Hungary 7 0 0.7 0 0 0 0
Iceland 0 0 0 0 0 0 0
Ireland 10 8 2.2 1.7 0 0 8
Israel 0 0 0 0 0 0 0
Italy 246 – 4.0 – – – –
Kazakhstan 25 36 1.5 2.2 34 0 2
Kyrgyzstan 4 12 0.7 2.2 12 0 0
Latvia 8 0 3.9 0 0 0 0
Lithuania 0 0 0 0 0 0 0
Luxembourg 1 0 1.9 0 0 0 0
Malta 1 0 2.3 0 0 0 0
Monaco 0 – 0 – – – –
Montenegro 0 0 0 0 0 0 0
Netherlands 1 57 0.1 3.4 20 37 0
Norway 1 3 0.2 0.6 3 0 0
Poland 6259 38 585 163.8 1009.6 0 0 38 585
Portugal 3 1 0.3 0.1 0 0 1
Republic of Moldova – 0 – 0 0 0 0
Romania 20 772 150 954.8 6.9 105 8 37
Russian Federation 1003 233 7.0 1.6 176 57 0
San Marino – – – – – – –
Serbia – – – – – – –
Slovakia 0 0 0 0 0 0 0
Slovenia 0 0 0 0 0 0 0
Spain 63 3 1.3 0.1 3 0 0
Sweden 50 0 5.3 0 0 0 0
Switzerland 8 7 1.0 0.9 7 0 0
Tajikistan 1 0 0.1 0 0 0 0
The former Yugoslav
Republic of Macedonia
2 0 0.9 0 0 0 0
Turkey – – – – – – –
Turkmenistan 0 0 0 0 0 0 0
Ukraine 942 9 20.7 0.2 0 8 1
United Kingdom 69 14 1.1 0.2 14 0 0
Uzbekistan 0 0 0 0 0 0 0
Total 29 601 39 367 45.5* 66.3* 397 113 38 857
Belgium, Denmark and France did not have a mandatory notiﬁcation system covering total population for reporting rubella cases in 2013. Germany introduced such a system in
2013 which is expected to become fully operational in 2014.
There may be differences in numbers documented in reports based on data derived from the WHO/UNICEF Joint Reporting Form – the data we present for 2012 include updated
numbers reported by some countries and for 2013, the data may be updated following the publication of this article. Discrepancies might also arise with nationally reported data if
these include cases by year of notiﬁcation rather than year of disease onset.
*Population of countries without reports were excluded from the denominator.
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for aggregate data collection with a limited set of variables.
However, a publication originating earlier in 2013 from the
National Institute of Public Health in Poland reported in a 2013
publication that most (81%) of the 21 283 cases of rubella
notiﬁed from January to April were among males 15–29 years
old. This reﬂects the history of immunization policies in
Poland: from 1989, adolescent girls were selectively vaccinated
and since 2004, a universal two-dose combined measles,
mumps and rubella (MMR) vaccination programme has been
implemented [14].
The aim of eliminating rubella is to prevent the occurrence
of congenital rubella syndrome (CRS). For 2012, 60 cases were
reported from six countries through the WHO/UNICEF Joint
Reporting Form [15]. Many countries in the Region have a
national mandatory notiﬁcation system for CRS [16]. How-
ever, high-quality surveillance in all countries is needed to
allow for a more accurate assessment of rubella vaccination
programmes.
High vaccination coverage (≥95%) with two doses of
measles vaccines and at least one dose of rubella vaccine in all
population groups and age cohorts is crucial to elimination.
Countries need to identify susceptible individuals and popu-
lation groups and consider undertaking catch-up immuniza-
tion or supplementary immunization activities to close
immunity gaps. Every opportunity should be used to reach
children with routine vaccination and to present adolescents
and adults with the option of checking their vaccination status
and receiving vaccinations that they may have missed. MMR
vaccination should also be recommended for susceptible
persons intending to travel to countries where measles is
endemic and where outbreaks are ongoing. To protect
healthcare workers, prevent nosocomial infections and limit
transmission of these diseases, healthcare workers should be
vaccinated [17,18]. Those with an uncertain vaccination status
or unknown history of disease should have their immunity
status checked and be vaccinated accordingly.
At the same time, there is a constant need to maintain
public and healthcare worker conﬁdence in vaccination and to
improve their understanding of the beneﬁts and risks
associated with vaccination against measles and rubella. As
these diseases become less frequent, concerns about them
tend to become overridden by concerns about vaccine safety.
The latter are often exacerbated by misinformation, in part
fostered by anti-vaccination groups. Therefore, health author-
ities should promptly investigate adverse effects following
vaccination and disseminate the results quickly and effectively.
Responding to public concerns in a timely and transparent
manner is crucial in building trust and allaying vaccine safety
fears. Health authorities should also provide the public and
healthcare workers with easy access to reliable information
on the beneﬁts of vaccination and on vaccine safety, as well as
on the severity of the diseases they prevent. In addition,
better tools to communicate these messages to parents and
patients should be developed and used.
We did not evaluate the surveillance systems and the extent
of implementation of case deﬁnitions used for reporting
measles and rubella by each country. The surveillance data we
collected are based on passive reporting of cases of disease
through routine surveillance systems. Although measles and
rubella are statutorily notiﬁable diseases in almost all coun-
tries, these systems are notorious for under-reporting and
incompleteness of data provided. Therefore, the required
sensitivity of surveillance systems appropriate for a disease
targeted for elimination may not have been achieved. Despite
these limitations, we present the best possible data that
national surveillance institutions could provide. During the
process of verifying the elimination of measles and rubella for
the Region, each country will need to evaluate their own
sensitivity of measles and rubella surveillance and identify areas
where the quality of surveillance can be improved [19].
The data we present for 2013 are to be considered as
preliminary because monthly reporting to the WHO Regional
Ofﬁce for Europe was not complete for the Region; a few
countries did not report at all or failed to submit some
monthly reports. This limits the accuracy of an epidemiological
assessment of measles and rubella and makes comparisons
between countries difﬁcult. Nevertheless, it is sufﬁciently clear
that the Region continues to face challenges in interrupting
endemic transmission of measles and rubella viruses.
Member States are reminded of their commitment to attain
and maintain very high population immunity for these diseases.
A ‘business as usual’ approach is not sufﬁcient to reach the
elimination target. For this reason, a Package for Accelerated
Action for measles and rubella elimination [20] was launched in
2013 to outline priority areas in which the WHO European
Regional Ofﬁce can provide technical support to Member
States. It also sets indicators and milestones by which progress
resulting from the efforts of all stakeholders can be measured.
Without sustained political commitment, determination, appro-
priate legislation, increased investment, and accelerated action
by Member States and partners, the elimination of measles and
rubella in the WHO European Region may not be achieved.
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